


#140/12
04-14-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In the Application of:

ANDERSON and GALIBERT

Serial No: 09/705,985

Filed: November 3, 2000

For: METHOD OF INHIBITING OSTEOCLAST ACTIVITY

Docket No.: 2874-B

Confirmation No. 6890

Group Art Unit: 1646

Examiner: N. Basi

RECEIVED

APR 14 2003

TECH CENTER 1600/2900

AMENDMENT and
RESPONSE TO PAPER NO. 12

Commissioner for Patents
Washington, DC 20231

In response to the Examiner's Action (Paper No. 12) mailed November 4, 2002, please enter the following amendments into the application:

In the Claims:

Please amend the claims as follows:

D1
5. (Three times amended) A method of inhibiting RANKL-induced osteoclastogenesis in a patient in need thereof, comprising administering to said patient a soluble RANK polypeptide composition, wherein said patient suffers from a condition selected from the group consisting of bone cancer, multiple myeloma, melanoma and breast cancer, and further wherein the soluble RANK polypeptide is capable of binding to a RANKL polypeptide that consists of amino acids 1-317 of SEQ ID NO:8 and is selected from the group consisting of:

(a) a polypeptide encoded by a DNA that encodes a protein comprising amino acids 33-196 of SEQ ID NO:2;

(b) a polypeptide encoded by a DNA that is capable of hybridizing to a DNA consisting of the nucleotide sequence shown in SEQ ID NO:1 under stringent conditions, wherein stringent conditions comprise hybridizing at 63°C in 6 x SSC;

(c) a polypeptide that is at least 80% identical in amino acid sequence to a RANK polypeptide comprising amino acids [1]33-213 of SEQ ID NO:2; and

(d) a polypeptide comprising amino acids 33-213 of SEQ ID NO:2, and further wherein said composition is administered in amounts sufficient to inhibit RANKL-induced osteoclastogenesis in said patient.

D2
9. (Twice amended) The method of claim 5, wherein the soluble RANK further comprises a polypeptide selected from the group consisting of an immunoglobulin